NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Kalpataru Ltd Seeks Shareholder Approval for Material Related Party Transactions
Kalpataru Limited has issued a postal ballot notice to seek shareholder approval for several material related party transactions (RPTs). The proposed resolutions include transactions with its subsidiaries, Kalpataru Properties (Thane) and Agile Real Estate Dev, as well as various promoter group entities and the Managing Director, Mr. Parag M. Munot. Notably, one resolution involves providing financial assistance via Inter Corporate Deposits to its subsidiary, Agile Real Estate Dev. The e-voting period is set for January 03 to February 01, 2026, with results to be announced by February 03, 2026.
முக்கிய அம்சங்கள்
Postal ballot notice dispatched on January 02, 2026, for three ordinary resolutions regarding material RPTs.Resolution 2 specifically seeks approval for extending financial assistance via Inter Corporate Deposits to subsidiary Agile Real Estate Dev.Resolution 3 involves transactions with multiple promoter group entities and the Managing Director, Mr. Parag M. Munot.The remote e-voting window is open for 30 days, starting January 03, 2026, and concluding on February 01, 2026.The cut-off date for determining shareholder eligibility for voting was Friday, December 26, 2025.
👀 கவனிக்க வேண்டியவை
Investors should carefully review the explanatory statement in the postal ballot notice to assess the terms and arm's-length nature of these transactions, particularly the financial assistance to subsidiaries. Monitor the voting results on February 03, 2026, as these transactions can impact the company's cash flow and governance profile.
Kalpataru Ltd Receives ₹80.71 Crore GST Tax Demand and Penalty Order
Kalpataru Limited has received a formal tax demand order (DRC-07) from the CGST Mumbai authorities totaling ₹80.71 crores. The demand relates to alleged non-payment of GST on flats allotted to society members in exchange for development rights during FY 2018-19. The total amount includes ₹40.36 crores in tax and an equivalent ₹40.36 crores in penalties. The company plans to appeal the order and currently expects no material financial impact.
முக்கிய அம்சங்கள்
Total tax demand and penalty amounting to ₹80,71,45,860.Demand includes ₹40.36 crore in tax and ₹40.36 crore in penalties under Section 74 of the GST Act.The dispute involves GST on flats provided to members for transfer of development rights in FY 2018-19.The company intends to challenge the order before the Appellate Authority.This matter was previously disclosed in the company's Red Herring Prospectus dated June 18, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the appeal as an adverse final ruling could impact the company's cash flows, though the issue was previously disclosed in IPO documents.
Dr. Lal Path Labs Allots 8.37 Crore Bonus Shares in 1:1 Ratio
Dr. Lal Path Labs has completed the allotment of 8,37,75,510 bonus equity shares to eligible shareholders following its 1:1 bonus issue. The allotment was approved via a circular resolution on December 22, 2025, for shareholders on record as of December 19, 2025. This move doubles the company's total number of outstanding shares to 16,75,51,020. The paid-up equity share capital now stands increased at INR 167.55 crore, with the new shares ranking pari-passu with existing ones.
முக்கிய அம்சங்கள்
Allotment of 8,37,75,510 fully paid-up bonus equity shares of face value INR 10 each.Bonus issue executed in a 1:1 ratio for shareholders as of the December 19, 2025 record date.Total paid-up equity capital increased from INR 83.77 crore to INR 167.55 crore.Total number of equity shares outstanding increased to 16,75,51,020 shares.New bonus shares rank pari-passu in all respects with existing equity shares.
👀 கவனிக்க வேண்டியவை
Investors should note that while the number of shares in their portfolio has doubled, the stock price has been adjusted proportionally. No further action is required as the allotment is automatic for eligible shareholders.
Dr. Lal Path Labs Sets Dec 19 as Record Date for 1:1 Bonus Issue
Dr. Lal Path Labs Ltd. has officially fixed Friday, December 19, 2025, as the record date for its 1:1 bonus share issue. Eligible shareholders will receive one new fully paid-up equity share of INR 10 for every one existing share held. The deemed date for the allotment of these bonus shares is scheduled for December 22, 2025. This corporate action follows the approval previously granted by the company's members on December 08, 2025.
முக்கிய அம்சங்கள்
Bonus issue ratio confirmed at 1:1 (one new share for every one existing share).Record date for determining shareholder eligibility is December 19, 2025.Deemed date of allotment for the bonus equity shares is December 22, 2025.The face value of the equity shares remains unchanged at INR 10 per share.
👀 கவனிக்க வேண்டியவை
Investors should note that the stock price will adjust downward on the ex-bonus date to reflect the 1:1 ratio, while their total shareholding will double. To be eligible for the bonus, shares must be purchased before the ex-date.
Kalpataru Limited Withdraws Demerger Scheme for Project Yoganand
Kalpataru Limited has officially withdrawn its proposed Scheme of Arrangement for the demerger of Project Yoganand, located in Borivali, Mumbai. The project was initially intended to be transferred to its wholly-owned subsidiary, Kalpataru Residency Private Limited. The National Company Law Tribunal (NCLT), Mumbai Bench, has formally allowed this withdrawal as per its order dated November 25, 2025. This decision reverses the previous board approval, meaning the specific real estate asset will remain within the main listed entity's direct portfolio.
முக்கிய அம்சங்கள்
Withdrawal of demerger scheme for Project Yoganand situated at Borivali, MumbaiNCLT Mumbai Bench allowed the withdrawal of the application via order dated Nov 25, 2025The project will no longer be transferred to the subsidiary Kalpataru Residency Private LimitedThe Board of Directors had previously approved the withdrawal of the scheme on Nov 10, 2025
👀 கவனிக்க வேண்டியவை
Investors should note that the asset remains with the parent company, maintaining the status quo on the balance sheet. Monitor for management commentary regarding the change in corporate restructuring strategy.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Dr. Lal PathLabs Q2 FY26 Net Profit Rises 16.4% YoY to ₹152 Cr; 1:1 Bonus Issue Approved
Dr. Lal PathLabs reported a steady performance for Q2 FY26, with revenue from operations growing 10.7% YoY to ₹730.6 crore. Net profit for the quarter increased by 16.4% YoY to ₹152.2 crore, supported by a 10.8% growth in H1 revenue reaching ₹1,400.4 crore. The company's board has approved a 1:1 bonus issue and a second interim dividend of ₹7 per share, reflecting strong cash flows and management confidence. Operational highlights include the successful integration of Suburban Diagnostics' business into the parent entity following its voluntary liquidation.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.7% YoY to ₹7,306 million in Q2 FY26.Consolidated Net Profit rose 16.4% YoY to ₹1,522 million compared to ₹1,308 million in the previous year.Board approved a 1:1 bonus issue (one bonus share for every one share held) subject to shareholder approval.Declared a second interim dividend of ₹7 per equity share for FY26.Basic Earnings Per Share (EPS) improved to ₹18.05 from ₹15.52 in the same quarter last year.
👀 கவனிக்க வேண்டியவை
The consistent double-digit growth in profit and the announcement of a 1:1 bonus issue are strong positive signals for long-term investors. Maintain a positive outlook on the stock while monitoring the integration benefits of the Suburban Diagnostics business.
Dr. Lal PathLabs Increases Authorized Share Capital to INR 200 Crore
Dr. Lal PathLabs has received shareholder approval via postal ballot to significantly increase its authorized share capital. The limit has been raised from INR 107.96 crore to INR 200 crore, effectively doubling the company's capacity to issue new equity. This change involves a formal amendment to Clause V of the Memorandum of Association. While this is a regulatory enabling provision, it often serves as a precursor to future corporate actions such as bonus issues, rights issues, or equity-based fundraising.
முக்கிய அம்சங்கள்
Authorized share capital increased from INR 107.96 crore to INR 200 crore.Shareholder approval was obtained through a postal ballot concluded on December 07, 2025.The new capital structure consists of 20,00,00,000 equity shares with a face value of INR 10 each.Amendment to Clause V of the Memorandum of Association (MOA) has been officially implemented.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company for upcoming announcements regarding bonus issues or capital raises, as this move creates the necessary legal headroom for such actions.
Dr. Lal PathLabs Shareholders Approve Bonus Issue and New 2025 Employee Stock Unit Plan
Dr. Lal PathLabs has announced the successful passage of seven resolutions via postal ballot, most notably the issuance of bonus equity shares and an increase in authorized share capital. The 'Employee Restricted Stock Unit Plan 2025' was approved with 79.81% favor, although it faced significant institutional dissent with 51.5% of institutional votes cast against it. Additionally, shareholders cleared the path for secondary share acquisitions through a trust and a reduction in the 2022 options reserve. These approvals facilitate the company's capital restructuring and long-term incentive programs.
முக்கிய அம்சங்கள்
Bonus Equity Shares issuance approved with 98.04% of total votes in favor.Increase in Authorized Share Capital passed with a near-unanimous 99.84% majority.New 'Employee Restricted Stock Unit Plan 2025' secured 79.81% support despite 51.5% institutional pushback.Secondary acquisition of shares through a Trust route for ESOP implementation approved by 83.76% of voters.Reduction of Options Reserve under the 2022 ESOP plan approved with 86.80% majority.
👀 கவனிக்க வேண்டியவை
Investors should view the bonus issue as a positive move for share liquidity, though the high institutional dissent on the new ESOP plan suggests a need to monitor future management compensation and dilution.
Shalimar Paints Q2 Net Loss Narrows to ₹13.87 Cr; Revenue Dips 8.7% YoY
Shalimar Paints reported a narrowing of its standalone net loss to ₹13.87 crore for the quarter ended September 30, 2025, compared to a loss of ₹19.60 crore in the same period last year. Revenue from operations saw a year-on-year decline of 8.7%, falling to ₹132.11 crore from ₹144.74 crore. Despite the revenue dip, the company showed operational improvement in H1 FY26, with losses reducing to ₹30.53 crore from ₹46.62 crore and a significant improvement in operating cash flows.
முக்கிய அம்சங்கள்
Q2 FY26 revenue decreased 8.7% YoY to ₹132.11 crore from ₹144.74 crore.Standalone net loss narrowed to ₹13.87 crore in Q2 FY26 vs ₹19.60 crore in Q2 FY25.H1 FY26 net loss improved to ₹30.53 crore from ₹46.62 crore in H1 FY25, a 34.5% reduction.Operating cash flow usage reduced drastically to ₹2.25 crore in H1 FY26 from ₹74.60 crore in H1 FY25.Finance costs increased to ₹12.64 crore for H1 FY26 compared to ₹7.21 crore in H1 FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to reverse the revenue decline while continuing to narrow losses; the significant improvement in cash flow is a positive sign of operational stabilization.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
